BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ritter Pharmaceuticals, Inc. Release: Andrew Ritter Named Finalist in LA Business Journal's Annual Healthcare Leadership Awards


4/24/2013 10:16:53 AM

LOS ANGELES, CA--(Marketwired - April 23, 2013) - Andrew Ritter, president and CEO of Ritter Pharmaceuticals, Inc., was selected as a finalist for the third annual Healthcare Leadership Awards recently presented by The Los Angeles Business Journal. Andrew has been at the forefront of researching the physiological effects of lactose intolerance and has gathered the leading minds in the fields of gastroenterology and biological science to put the technology behind colonic adaptation to work against the condition. Andrew's leadership at Ritter Pharmaceuticals has positioned the company at the forefront of developing therapeutic treatments based on colonic adaptation which alters the microflora for digestive health benefits. Ritter's lead product is being developed to treat lactose intolerance.

The LA Business Journal honored their award recipients and finalists at a banquet on Thursday, April 18 and featured them in a special supplement to the publication, released on April 22. Andrew was recognized in the Research Executive category for his commitment to advancing the standard of lactose intolerant patient care by working to provide what may be the first medical treatment option for the more than 40 million Americans who suffer with mild to severe lactose intolerance.

"I am honored that the Los Angeles Business Journal's Awards committee has named me among the healthcare leaders in Los Angeles," said Andrew Ritter. "And, I applaud the Journal for acknowledging the important role that medical research has on our local economy and citizens," he added.

Ritter Pharmaceuticals

Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem. Ritter is rapidly establishing itself as the world's leader in lactose intolerance research and development. Ritter's RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance.


Media Contact:
Susan Rogers
susan@ritterpharma.com
650-430-3777
www.ritterpharmaceuticals.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES